logo
These 'steady compounders' have delivered superior earnings growth for the past decade, Bank of America says

These 'steady compounders' have delivered superior earnings growth for the past decade, Bank of America says

CNBC3 days ago
A slate of companies that have posted "consistent and superior" earnings growth over the past 10 years could be poised for strong performances and are worth watching, according to Bank of America. "Since data began in 1998, the Global Steady Compounders have annualized 5.2% outperformance versus the MSCI AC World Index and have outperformed in more months than most strategies we monitor," strategist Nigel Tupper wrote in a Tuesday note. "Stocks screening as Steady Compounders tend to outperform for extended periods." There are circumstances in which "steady compounders" don't fare well. Tupper wrote that the names tend to underperform when bond yields rise with inflation and in "significant" risk-on market periods, given that the stocks reflect earnings stability. The strategist screened for stocks that have an average score of above 95 out of 100 based on 10-year earnings growth, "stable" earnings growth, the stock's two-year earnings per share growth forecast, earnings revisions and its 12-month return. The current earnings season has been solid thus far, which has helped send the market to new highs . Of the 199 S & P 500 companies that have reported earnings, nearly 82% have beaten expectations, per FactSet. Here are some of the names that popped up in the U.S. "steady compounders" screen. Global payments technology company Visa was among the names tied for the highest score on the list, with a score of 100 in the steady compounders rank. Shares have outperformed the S & P 500 in 2025, rising nearly 12%, versus the broad market index's roughly 8% gain during the period. Visa is scheduled to report its quarterly results for the fiscal third quarter after the bell Tuesday. Analysts surveyed by LSEG are expecting the company to post double-digit-percentage earnings and revenue growth compared to the prior-year period. Most analysts on Wall Street are bullish on Visa, as 32 out of 40 total analysts have a strong buy or buy rating on the name, per LSEG data. Microsoft , which reports after the bell on Wednesday, had a score of 100 as well. Analysts expect the "Magnificent Seven" company to post around 14% earnings and revenue growth year over year. The stock has similarly outpaced the broader market, seeing a meaningful advance in 2025 of more than 21%. Like Visa, a majority of the Street is optimistic on the stock's trajectory over the next several months, with 56 among the 62 analysts covering it having a strong buy or buy rating. Financial technology platform Intuit also made the cut at 100 in the steady compounders rank. The stock has soared more than 27% in 2025 and around 35% over the past six months, outperforming the broader market. The company is slated to post its earnings results in late August.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

With UnitedHealth Group (UNH) Stock Down Over 50%, Let's Look at Who Owns It
With UnitedHealth Group (UNH) Stock Down Over 50%, Let's Look at Who Owns It

Business Insider

time19 minutes ago

  • Business Insider

With UnitedHealth Group (UNH) Stock Down Over 50%, Let's Look at Who Owns It

UnitedHealth Group (UNH) has had a rough ride in 2025. The stock is down over 56% year-to-date, hit by rising medical costs, a DOJ probe, executive changes, and now disappointing Q2 results. The company recently posted adjusted earnings per share of $4.08 on $111.6 billion in revenue, narrowly beating the revenue forecast but missing the EPS consensus of around $4.45. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Still, the company reaffirmed its full-year guidance and provided more clarity on its 2025–2026 outlook, prompting mixed reactions from analysts. For instance, analyst Lance Wilkes from Bernstein remains optimistic, citing UnitedHealth's strong market position and potential rebound in Medicare Advantage trends. In contrast, BofA analyst Kevin Fischbeck is more cautious, due to concerns over the company's slower growth pace. With the stock in focus, now's a good time to take a closer look at who actually owns UNH shares. Now, according to TipRanks' ownership page, public companies and individual investors own 45.60% of UNH. They are followed by mutual funds, ETFs, other institutional investors, and insiders at 28.84%, 23.20%, 2.19%, and 0.18%, respectively. Digging Deeper into UnitedHealth Group's Ownership Structure Looking closely at top shareholders, Vanguard owns the highest stake in UNH at 8.89%. Next up is Vanguard Index Funds, which holds a 7.03% stake in the company. Among the top ETF holders, the Vanguard Total Stock Market ETF (VTI) owns a 3.22% stake in UNH stock, followed by the Vanguard S&P 500 ETF (VOO), with a 2.84% stake. Moving to mutual funds, Vanguard Index Funds holds about 7.03% of UNH. Meanwhile, Fidelity Concord Street Trust owns 1.72% of the company. Is UNH a Good Buy Now? Turning to Wall Street, UNH stock has a Moderate Buy consensus rating based on 18 Buys, three Holds, and two Sells assigned in the last three months. At $321.76, the average UnitedHealth stock price target implies a 28.93% upside potential.

Is Visa (V) a Smart Buy and Hold Stock in the Tech-Driven Market?
Is Visa (V) a Smart Buy and Hold Stock in the Tech-Driven Market?

Yahoo

time32 minutes ago

  • Yahoo

Is Visa (V) a Smart Buy and Hold Stock in the Tech-Driven Market?

Visa Inc. (NYSE:V) is included among the 10 Best Dividend Stocks to Buy and Hold Forever. siam sompunya The company is embracing AI to stay ahead, launching its Intelligent Commerce platform that uses AI agents for shopping, digital credentials, and personalized payment insights. It's working with top tech firms like OpenAI and Microsoft, and has upgraded its platform with AI features. Visa also acquired AI-based fraud detection firm Featurespace to boost security. On the financial side, Visa Inc. (NYSE:V) is a strong dividend stock with 17 years of consecutive increases and a low 18.5% payout ratio. As a payment processor, it profits from card usage without lending risk, making it a reliable stock in any economy. Over the past decade, the company has delivered an impressive annualized dividend growth rate of 17%. While recent increases have been slightly more modest, the one-, three-, and five-year growth rates all remain above 10%, making Visa a strong pick for dividend growth investors. On July 29, Visa Inc. (NYSE:V) declared a quarterly dividend of $0.59 per share, which fell in line with its previous dividend. As of July 31, the stock has a dividend yield of 0.68%. While we acknowledge the potential of V as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

How Will VRTX Stock React To Its Upcoming Earnings?
How Will VRTX Stock React To Its Upcoming Earnings?

Forbes

time34 minutes ago

  • Forbes

How Will VRTX Stock React To Its Upcoming Earnings?

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, August 4, 2025. Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings announcements. The median positive return has been 3.0%, with a maximum one-day increase of 9.0%. For those trading based on events, recognizing these historical trends can prove advantageous, although actual performance against expectations will be crucial. There are two primary strategies to think about: Analysts anticipate Vertex will disclose earnings of $4.25 per share, generating a revenue of $2.91 billion. This marks a considerable improvement compared to the same quarter last year, which reported a loss of $12.83 per share on sales of $2.65 billion. However, if you are looking for upside with reduced volatility compared to individual stocks, the Trefis High Quality portfolio offers an alternative – having outperformed the S&P 500 and achieved returns exceeding 91% since its launch. View earnings reaction history of all stocks Vertex Pharmaceuticals' Historical Probability of Positive Post-Earnings Return Some insights regarding one-day (1D) post-earnings returns: Further information on observed 5-Day (5D) and 21-Day (21D) returns following earnings is summarized in the table below along with the related statistics. Correlation Between 1D, 5D and 21D Historical Returns A comparatively lower-risk approach (though not effective if the correlation is weak) is to evaluate the correlation between short-term and medium-term returns after earnings, identify the pair that exhibits the strongest correlation, and perform the proper trade. For instance, if 1D and 5D display the highest correlation, a trader can place themselves "long" for the forthcoming 5 days if the 1D post-earnings return is favorable. Below is some correlation data based on both a 5-year and a 3-year (more recent) history. Please note that the correlation 1D_5D indicates the relationship between 1D post-earnings returns and subsequent 5D returns. Discover more about Trefis RV strategy that has outperformed its all-cap stocks benchmark (the combination of all 3, the S&P 500, S&P mid-cap, and Russell 2000), providing strong returns for stakeholders. Additionally, if you're seeking upside with a more stable journey than an individual stock like Vertex Pharmaceuticals, think about the High Quality portfolio, which has outperformed the S&P and achieved >91% returns since its inception.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store